CliffBio
small molecule

IMIQUIMOD

IMIQUIMOD

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameIMIQUIMOD
Active ingredientIMIQUIMOD
Strength5%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalApril 2012
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.